AI assistant
Cidara Therapeutics, Inc. — Director's Dealing 2021
Jul 19, 2021
31535_dirs_2021-07-19_4aade774-5786-4563-a487-cef21c353b8d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Cidara Therapeutics, Inc. (CDTX)
CIK: 0001610618
Period of Report: 2021-07-09
Reporting Person: Johnson Brady (Vice President, Finance)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 26369 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.45 | 2026-12-17 | Common Stock (12111) | Direct | |
| Stock Option (right to buy) | $2.45 | 2026-12-17 | Common Stock (20012) | Direct | |
| Stock Option (right to buy) | $1.98 | 2030-03-18 | Common Stock (6700) | Direct | |
| Stock Option (right to buy) | $2.55 | 2031-03-16 | Common Stock (12150) | Direct | |
| Restricted Stock Unit | $ | Common Stock (524) | Direct |
Footnotes
F1: One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.
F2: Shares are fully vested
F3: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.
F4: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.
F5: The shares shall vest upon the achievement of various clinical and corporate milestones.
F6: Restricted stock units convert into common stock on a one-for-one basis.